




Glumetza[®]
(metformin HCl extended release tablets)

Bring more of your
patients to HbA_{1c} goal

GLUMETZA[®] Advanced polymer technology* may help reduce GI adverse events in your patients and bring more of them to HbA_{1c} goal.

Dear Dr. Bizzak,

This email is designed to provide you easy access to information on the **technology, tolerability, and A 1c control of GLUMETZA:**

- Advanced polymer delivery technology^{1,2} may help reduce GI adverse events
- Well tolerated, with no significant increase in adverse events at higher doses^{2,3}
 - As observed in a clinical trial, overall incidence of drug-related adverse events was 35% for Glucophage[®] (metformin hydrochloride tablets) 1500 mg/day BID and 33% for GLUMETZA dosed up to 2000 mg QD^{3†}
- GLUMETZA 1000 mg tablet adds convenience by minimizing pill burden
- Covered by most formularies and PBMs⁴

In clinical trials, the most common side effects with GLUMETZA monotherapy were diarrhea, nausea, dyspepsia, and upper abdominal pain. In a clinical trial of GLUMETZA combined with a sulfonylurea, the most common side effects included hypoglycemia, diarrhea, and nausea.

We invite you to explore GLUMETZA on your personal micro-site and receive a complimentary 3-month epocrates[®] subscription.†

www.hbagoals.com/message4/JamieBizzak

†Please note only one subscription per physician

Thank you for choosing GLUMETZA. We hope you found this information useful.

Best regards,



Learn more about GLUMETZA, plus receive complimentary 3-month epocrates[®] subscription

Plus...

- 2-question survey
- Request educational support materials for your practice
- Request samples
- Request a representative visit



Important Safety Information about GLUMETZA

- As with all metformin products, lactic acidosis due to metformin accumulation during treatment with GLUMETZA is a rare but potentially fatal occurrence
 - May also occur in association with a number of pathophysiologic conditions